Shares in Frontier IP Group PLC (LSE:FIPP, FRA:8WT) rose 4% to 14.5p after it told investors that portfolio company inSignals Neurotech has secured a €317,762 grant to push its Parkinson’s disease monitoring technology beyond clinical settings and into everyday wearable devices.
The grant, co-financed by the European Union under the Portugal 2030 framework through the NORTE 2030 programme, will fund work to extend inSignals’ proprietary algorithms to third-party wearables including smartwatches and smart rings.
Frontier IP, which holds a 32.9% equity stake in inSignals, said the move builds on clinically validated technology designed to enable continuous, real-world monitoring of Parkinson’s disease.
The company said this could support more responsive treatment optimisation, including integration with advanced therapies such as deep brain stimulation.
Separately, inSignals is launching a mobile app for Parkinson’s patients and caregivers, funded by a previous PRR Green Vouchers grant, to support symptom monitoring and communication with clinicians.
The company is also undertaking a seed fundraising round to support medical regulatory compliance and international expansion.
Its technology has been tested in more than 200 patients across an international multi-centre clinical study, with patents covering rigidity quantification methods.
Shore Capital called Monday's news 'positive', though its note also focused on the potential value realisation from key elements of its portfolio.
"When one core investment is realised in cash, in our view, FIPP will be able to support existing and future investments, buy back shares and potentially seed a VC fund," the broker told investors.
----ADDS SHARE PRICE AND BROKER COMMENT----
